You searched for "complication"

2911 results found

The sexist lens addressing cataract-induced blindness in women

Ninety percent of the world’s blind population resides in low-income, developing countries [1]. The primary cause of their blindness is cataract, a condition that is easily treatable and unnecessary. A cataract is the clouding of the eye’s lens, often resulting...

MicroPulse Transscleral Laser Therapy: A Prospective UK Study

Register now to participate. Eagerly anticipated and now underway – a landmark UK medical research study on MicroPulse® Transscleral Laser Therapy (MPTLT) for the treatment of glaucoma using Iridex’ Cyclo G6® Laser and the MicroPulse P3® Delivery Device. A NICE-compliant...

The effects of anti-VEGF therapy for NvAMD on retinal vasculature

This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...

Jessica Bartlett joins Glaukos as Territory Manager, North West England / Yorkshire

Glaukos Corporation is delighted to announce the appointment of Jessica Bartlett to the position of Territory Manager, Northwest, and Yorkshire.

Simon Lysaght joins Glaukos as Territory Manager, Ireland

Glaukos Corporation is delighted to announce the appointment of Simon Lysaght to the position of Territory Manager, Ireland.

Raphaél Ervinckx joins Glaukos

Glaukos Corporation has appointed Raphaél Ervinckx as Vice President and General Manager for the EMEAI region, marking a strategic move to support the company’s continued international growth. Raphaël Ervinckx brings extensive experience in the ophthalmology sector, most recently serving as...

Graham Popham joins Glaukos as Senior Director, Market Access EMEAI

Glaukos are delighted to announce the appointment of Graham Popham as Senior Director, Market Access EMEAI. Graham comments: "’I'm excited to join Glaukos at such a pivotal time in the evolution of ophthalmic care and growth of the organisation. Throughout...

Dementia and visual impairment: what is the relationship and are we providing the best care?

Carla Maden discusses the implications of living with both dementia and visual impairment, and how general medical junior doctors and ophthalmologists can help to alleviate this burden and improve the quality of life of such patients. Dementia and visual impairment...

Use of RAPDx device with optic nerve disease

The authors have previously reported on use of the RAPDx device for evaluating relative afferent pupillary defects (RAPD). RAPDx objectively determines the magnitude of RAPD by presenting light stimuli alternately to pairs of eyes with laterality. The parameters of amplitude...

Glaucoma care provision using a multidisciplinary approach: a personal view

This article is going to explain the secret to running an efficient multidisciplinary glaucoma service which will comfortably meet the demands of an ever-growing elderly population, within the confines of budgetary and clinical constraints, wherever the setting. This may be...

Will it change management?

Like most doctors I have read and am a fan of Samuel Shem’s House of God, with my favourite Rule being Rule 10: “If you don’t take a temperature you can’t find a fever.” If you don’t intend to treat...

Cytokine levels in vitreous fluid in patients with pathological myopia

Pathological myopia (PM) is a leading cause of irreversible visual impairment worldwide, and efforts are dedicated to the study of its underlying mechanisms. Axial extension of the eyeball is regulated via a cascade of biochemical molecules that are initiated in...